News

Professor Mark JS Miller, Chairman of RNI’s Scientific Advisory Board, has been invited to present at the combined meeting of the British Inflammation Research Association and British Society for Immunology. His work on Reparagen will be detailed in the presentation entitled “Natural products from the Amazon Rainforest: from Jungle to bench to bedside” at the “Natural products in inflammation and chronic diseases” symposia. Due to ill health however, Professor Miller was not able to present the lecture but it was given by Professor Haqqi, who is also on the Scientific Advisory Board for Reparagen. read more

RNI presented its research findings that form the foundation of Reparagen at the World Congress of Inflammation in Melbourne, Australia in August 2005. read more

RNI’s research which was presented at the World Congress of Inflammation in Melbourne, Australia was published in Inflammation Research 54: Supplement 2, pp 115, 2005. The paper was entitled “Transcriptional activation of IGF-1 production in human cartilage explants concomitant with the prevention of IL-1 induced catabolism by a natural product, IGFlex.” read more

RNI was awarded a prestigious Innovation Research Award (SBIR) for its Phase I grant for the research and development of Reparagen for joint health in July 2004. This award (R43 AG024773-01) was from the USA’s NIH National Institute on Aging. read more

Results of our NIH funded research in collaboration with the faculty of Case Western Reserve University School of Medicine and Albany Medical College has been published. The article, which can be downloaded for free from the publisher, describes for the first time the ability of Reparagen to maintain the activity of the master repair gene, IGF-1, in human cartilage despite inflammation. This is the first time any therapeutic entity has been able to achieve this vital action. With mechanism of action joint repair can now be initiated and directed. read more

Controlled clinical trials (CCT), an international agency that reviews randomized clinical trials, has reviewed the current clinical trial for Reparagen in the treatment of moderate osteoarthritis of the knee. The trial is designed and executed by the contract research organization, Santerra Pharmaceuticals (http://www.santerra-pharma.com/) and compares Reparagen with Glucosamine. read more

Following the publication of the breakthrough research results for Reparagen in BMC Complementary and Alternative Medicine (http://www.biomedcentral.com/1472-6882/6/13), Dr. Miller, the primary author of the paper, was interviewed by WTEN News, an ABC affiliate. Dr. Miller described the critical importance and unique actions of reparagen and its ability to promote joint repair. read more